CU20120019A7 - Anticuerpos muc1 - Google Patents

Anticuerpos muc1

Info

Publication number
CU20120019A7
CU20120019A7 CU20120019A CU20120019A CU20120019A7 CU 20120019 A7 CU20120019 A7 CU 20120019A7 CU 20120019 A CU20120019 A CU 20120019A CU 20120019 A CU20120019 A CU 20120019A CU 20120019 A7 CU20120019 A7 CU 20120019A7
Authority
CU
Cuba
Prior art keywords
muc1 antibodies
antibodies
present
recognition
muc1
Prior art date
Application number
CU20120019A
Other languages
English (en)
Other versions
CU23972B1 (es
Inventor
Uwe Karsten
Renate Stahn
Antje Danielczyk
Steffen Goletz
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of CU20120019A7 publication Critical patent/CU20120019A7/es
Publication of CU23972B1 publication Critical patent/CU23972B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos antimucina con mejores propiedades de unión y/o reconocimiento de antígeno así como un procedimiento para mejorar la unión y/o reconocimiento de antígeno de un anticuerpo antimucina. En particular, la presente invención está dirigida a anticuerpos anti-MUC1 útiles en el tratamiento del cáncer.
CU2012000019A 2009-07-31 2012-01-30 Anticuerpos muc1 CU23972B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies

Publications (2)

Publication Number Publication Date
CU20120019A7 true CU20120019A7 (es) 2012-06-21
CU23972B1 CU23972B1 (es) 2013-12-27

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000019A CU23972B1 (es) 2009-07-31 2012-01-30 Anticuerpos muc1

Country Status (17)

Country Link
US (1) US9217038B2 (es)
EP (3) EP2281844A1 (es)
JP (2) JP5922018B2 (es)
KR (1) KR101773506B1 (es)
CN (1) CN102574926B (es)
AR (1) AR077334A1 (es)
AU (1) AU2010278302B2 (es)
BR (1) BR112012002226A2 (es)
CA (1) CA2768888C (es)
CU (1) CU23972B1 (es)
EA (1) EA029954B1 (es)
IL (1) IL217827A (es)
MX (1) MX2012000874A (es)
NZ (1) NZ597563A (es)
SG (2) SG10201404019XA (es)
WO (1) WO2011012309A1 (es)
ZA (1) ZA201200166B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2073842T4 (da) 2006-09-10 2024-01-15 Glycotope Gmbh Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
DK2603528T3 (en) 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
WO2013026887A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
US9873920B2 (en) 2013-03-01 2018-01-23 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting MUC4 gene polymorphism
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3127919A4 (en) 2014-02-06 2017-08-16 Medicinal Chemistry Pharmaceuticals Co., Ltd. Antibody against mucin 4 (muc 4) glycopeptide and use therefor
EP3150634B1 (en) * 2014-04-28 2020-04-22 Medicinal Chemistry Pharmaceuticals Co., Ltd. Anti-muc1 antibody or antigen-binding fragment thereof, and uses thereof
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
EP3570881A4 (en) * 2017-01-18 2020-08-19 Nanocruise Pharmaceutical Ltd. MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE
CN110177807B (zh) * 2017-01-27 2024-02-23 葛莱高托普有限公司 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗
CN110382541A (zh) 2017-03-29 2019-10-25 葛莱高托普有限公司 人源化抗cd40抗体
CA3055438A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
JP7360766B2 (ja) * 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
RS64379B1 (sr) * 2018-05-18 2023-08-31 Glycotope Gmbh Anti-muc1 antitelo
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
US20210269552A1 (en) * 2018-06-29 2021-09-02 Go Therapeutics, Inc. Anti-glyco-muc1 antibodies and their uses
TW202102228A (zh) 2019-03-25 2021-01-16 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物
WO2020196712A1 (ja) 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
CA2118010C (en) 1992-04-13 2003-10-28 Donald Kufe Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
WO2004009632A2 (de) 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
US8609370B2 (en) 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
DK2073842T4 (da) 2006-09-10 2024-01-15 Glycotope Gmbh Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Also Published As

Publication number Publication date
US9217038B2 (en) 2015-12-22
IL217827A0 (en) 2012-03-29
MX2012000874A (es) 2012-02-01
CN102574926A (zh) 2012-07-11
EA201270207A1 (ru) 2012-07-30
CN102574926B (zh) 2014-10-15
BR112012002226A2 (pt) 2016-11-08
KR20120051724A (ko) 2012-05-22
IL217827A (en) 2017-05-29
WO2011012309A1 (en) 2011-02-03
EA029954B1 (ru) 2018-06-29
JP6272916B2 (ja) 2018-01-31
AU2010278302B2 (en) 2014-12-18
EP2459595A1 (en) 2012-06-06
NZ597563A (en) 2013-08-30
CA2768888C (en) 2019-02-26
CA2768888A1 (en) 2011-02-03
JP2013500703A (ja) 2013-01-10
EP3421497A1 (en) 2019-01-02
KR101773506B1 (ko) 2017-08-31
US20120128676A1 (en) 2012-05-24
SG10201404019XA (en) 2014-09-26
EP2281844A1 (en) 2011-02-09
CU23972B1 (es) 2013-12-27
AR077334A1 (es) 2011-08-17
AU2010278302A1 (en) 2012-02-09
JP5922018B2 (ja) 2016-05-24
ZA201200166B (en) 2013-03-27
JP2016041771A (ja) 2016-03-31
SG177527A1 (en) 2012-02-28
WO2011012309A8 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CU20120019A7 (es) Anticuerpos muc1
TN2015000396A1 (en) Antibody drug conjugates
CY1122978T1 (el) Αντισωματα εναντι-vla-4
BR112012016742A2 (pt) metodos para tratamento de cancer pancreatico
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
CR20120036A (es) Terapia de combinación de un anticuerpo cd20 afucosilado y bendamustina
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
WO2012092336A3 (en) Molecular profiling for cancer
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
UY33591A (es) Nuevas proteínas de unión a antígenos
TN2016000577A1 (en) Anti-cdh6 antibody drug conjugates
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
EA201201474A1 (ru) Способы лечения рака молочной железы
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX2016004420A (es) Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.

Legal Events

Date Code Title Description
FG Grant of patent